Literature DB >> 578647

Passage of digoxin into cerebrospinal fluid in man.

H Allonen, K E Anderson, E Iisalo, J Kanto, L G Strömblad, G Wettrell.   

Abstract

The passage of digoxin into the cerebrospinal fluid (CSF) was studied in 8 infants on maintenance therapy with digoxin, 11 adult patients on long-term digoxin therapy, and 15 patients, previously non-digitalized, who were given 0.5 mg digoxin orally 1 hr to 12 hrs prior to lumbar puncture. Digoxin in the serum and CSF was determined by radioimmunoassay. In the infants a mean serum concentration of 1.5 ng/ml (range 0.7-2.3 ng/ml) was found, and a simultaneous mean CSF concentration of 0.5 ng/ml (range 0.3-1.1 ng/ml). In the adults on long-term therapy, the corresponding figures were 1.1 ng/ml (range 0.5-2.2 ng/ml) and 0.3 ng/ml (range 0-0.6 ng/ml). Among the 15 patients given a single oral dose of digoxin, detectable CSF concentrations (0.2-0.3 ng/ml) were found in five, 1-12 hrs after the administration of the drug. In three paediatric patients with hydrocephalus (3 months-5 years) digoxin therapy was started as an attempt to decrease CSF production. In these patients, the production of CSF was reduced by 17, 25 and 30%, respectively.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 578647     DOI: 10.1111/j.1600-0773.1977.tb02139.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  9 in total

Review 1.  Clinical pharmacokinetics of cerebrospinal fluid.

Authors:  M Bonati; J Kanto; G Tognoni
Journal:  Clin Pharmacokinet       Date:  1982 Jul-Aug       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of digoxin 1980.

Authors:  J K Aronson
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

3.  Use of cardiac glycosides and risk of glioma.

Authors:  Corinna Seliger; Christoph R Meier; Susan S Jick; Martin Uhl; Ulrich Bogdahn; Peter Hau; M F Leitzmann
Journal:  J Neurooncol       Date:  2015-12-31       Impact factor: 4.130

Review 4.  Clinical pharmacokinetics of digoxin.

Authors:  E Iisalo
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

5.  Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.

Authors:  Lei Huang; Sarah Garrett Injac; Kemi Cui; Frank Braun; Qi Lin; Yuchen Du; Huiyuan Zhang; Mari Kogiso; Holly Lindsay; Sibo Zhao; Patricia Baxter; Adesina Adekunle; Tsz-Kwong Man; Hong Zhao; Xiao-Nan Li; Ching C Lau; Stephen T C Wong
Journal:  Sci Transl Med       Date:  2018-10-24       Impact factor: 17.956

Review 6.  Nonsurgical therapy for hydrocephalus: a comprehensive and critical review.

Authors:  Marc R Del Bigio; Domenico L Di Curzio
Journal:  Fluids Barriers CNS       Date:  2016-02-05

7.  Microdialysis in awake macaque monkeys for central nervous system pharmacokinetics.

Authors:  Thibaud Thiollier; Caisheng Wu; Gregory Porras; Erwan Bezard; Qin Li; Jinlan Zhang; Hugues Contamin
Journal:  Animal Model Exp Med       Date:  2018-12-04

8.  Modelling the Human Blood-Brain Barrier in Huntington Disease.

Authors:  Domenico Vignone; Odalys Gonzalez Paz; Ivan Fini; Antonella Cellucci; Giulio Auciello; Maria Rosaria Battista; Isabelle Gloaguen; Silvia Fortuni; Cristina Cariulo; Vinod Khetarpal; Celia Dominguez; Ignacio Muñoz-Sanjuán; Annalise Di Marco
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

9.  Differences in P-glycoprotein activity in human and rodent blood-brain barrier assessed by mechanistic modelling.

Authors:  Laurens F M Verscheijden; Jan B Koenderink; Saskia N de Wildt; Frans G M Russel
Journal:  Arch Toxicol       Date:  2021-07-15       Impact factor: 5.153

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.